Baijin Life Science Holdings Limited (1466) issued a supplemental announcement dated 22 October 2025 regarding its proposed subscription of new shares under a general mandate. The announcement adds details on the use of proceeds and the background of the subscribers, following the initial disclosure on 29 September 2025.

According to the announcement, 60% of the net proceeds—approximately HK$11.5 million—will be allocated to repay bank borrowings, other borrowings, and payables by 31 March 2026. The remaining 40%—roughly HK$7.6 million—will serve as general working capital for the Group by 30 September 2026, covering expenses such as audit and professional fees, payroll, and rental payments. The Board anticipates that paying down loans early will help reduce interest expenses without affecting the existing cash position.

The subscribers include an owner of a construction company in China, a technology professional in China, and a chief accountant for a retail and commercial bank in China. All three participate as new investors only, with no relationship to one another or prior business ties to the Group, and no plans to become involved in the Group’s operations.

All other information from the 29 September 2025 announcement remains unchanged.